新型慢性淋巴细胞白血病药物。
Novel agents for chronic lymphocytic leukemia.
机构信息
Department of Hematology, First Hospital of Quanzhou affiliated to Fujian Medical University, Quanzhou, 362000, China.
出版信息
J Hematol Oncol. 2013 May 16;6:36. doi: 10.1186/1756-8722-6-36.
Abstract
Chronic lymphocytic leukemia (CLL) is a heterogeneous group of B-cell neoplasm. CLL is typically sensitive to a variety of cytotoxic agents, but relapse frequently occurs with conventional approaches. The treatment of CLL is evolving rapidly with the introduction of novel drugs, such as bendamustine, ofatumumab, lenalidomide, ibrutinib, idelalisib, veltuzumab, XmAb5574, navitoclax, dasatinib, alvespimycin, and TRU-016. This review summarizes the most current clinical experiences with these agents in the treatment of CLL.
摘要
慢性淋巴细胞白血病（CLL）是一组异质性 B 细胞肿瘤。CLL 通常对多种细胞毒药物敏感，但采用常规方法治疗时经常会复发。随着新型药物如苯达莫司汀、奥法妥木单抗、来那度胺、依鲁替尼、idelalisib、veltuzumab、XmAb5574、navitoclax、达沙替尼、alvespimycin 和 TRU-016 的引入，CLL 的治疗正在迅速发展。这篇综述总结了这些药物在 CLL 治疗中的最新临床经验。
相似文献
1
Novel agents for chronic lymphocytic leukemia.新型慢性淋巴细胞白血病药物。
J Hematol Oncol. 2013 May 16;6:36. doi: 10.1186/1756-8722-6-36.
2
Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.苯达莫司汀治疗慢性淋巴细胞白血病：结果与未来展望
Semin Oncol. 2002 Aug;29(4 Suppl 13):19-22. doi: 10.1053/sonc.2002.34875.
3
Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.用沙利度胺和来那度胺治疗慢性淋巴细胞白血病。
Expert Opin Pharmacother. 2011 Dec;12(18):2857-64. doi: 10.1517/14656566.2011.635644.
4
Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.慢性淋巴细胞白血病的新型药物：新疗法的疗效与耐受性
Clin Lymphoma Myeloma. 2008 Aug;8 Suppl 4:S137-43. doi: 10.3816/CLM.2008.s.009.
5
Bendamustine in the treatment of chronic lymphocytic leukemia.苯达莫司汀治疗慢性淋巴细胞白血病。
Expert Rev Anticancer Ther. 2009 Feb;9(2):165-74. doi: 10.1586/14737140.9.2.165.
6
Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.苯达莫司汀治疗慢性淋巴细胞白血病：未来是联合疗法。
Leuk Lymphoma. 2009 Sep;50(9):1399-400. doi: 10.1080/10428190903207563.
7
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.复发慢性淋巴细胞白血病化疗联合标准剂量或大剂量奥法木单抗（COSMIC）试验：一项II期随机对照试验的研究方案
Trials. 2016 Sep 20;17(1):456. doi: 10.1186/s13063-016-1581-0.
8
[Chronic lymphocytic leukemia].[慢性淋巴细胞白血病]
Rinsho Ketsueki. 2014 Feb;55(2):213-22.
9
Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia.奥法木单抗与苯达莫司汀联合治疗慢性淋巴细胞白血病异种移植模型。
Br J Haematol. 2012 Feb;156(3):402-4. doi: 10.1111/j.1365-2141.2011.08829.x. Epub 2011 Aug 18.
10
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.进入慢性淋巴细胞白血病的靶向治疗时代：对临床执业医师的影响
J Clin Oncol. 2014 Sep 20;32(27):3039-47. doi: 10.1200/JCO.2014.55.8262.
引用本文的文献
1
Immunotherapy in chronic lymphocytic leukemia: advances and challenges.慢性淋巴细胞白血病的免疫疗法：进展与挑战
Exp Hematol Oncol. 2025 Apr 10;14(1):53. doi: 10.1186/s40164-025-00644-5.
2
Organocatalysed synthesis of -(4-oxo-2-phenyl-1,2-dihydroquinazolin-3(4)-yl)isonicotinamide: computational, electrochemical, drug-likeness and antimicrobial studies.有机催化合成-(4-氧代-2-苯基-1,2-二氢喹唑啉-3(4)-基)异烟酰胺：计算、电化学、类药性及抗菌研究
3 Biotech. 2025 Jan;15(1):30. doi: 10.1007/s13205-024-04188-z. Epub 2025 Jan 3.
3
Ellagic acid, a polyphenolic compound, selectively induces ROS-mediated apoptosis in cancerous B-lymphocytes of CLL patients by directly targeting mitochondria.鞣花酸，一种多酚类化合物，通过直接靶向线粒体，选择性地诱导慢性淋巴细胞白血病（CLL）患者癌性B淋巴细胞中由活性氧（ROS）介导的细胞凋亡。
Redox Biol. 2015 Dec;6:461-471. doi: 10.1016/j.redox.2015.08.021. Epub 2015 Sep 10.
4
Ibrutinib: from bench side to clinical implications.依鲁替尼：从实验室到临床应用
Med Oncol. 2015 Sep;32(9):225. doi: 10.1007/s12032-015-0669-9. Epub 2015 Jul 30.
5
Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia.新型B细胞靶向药物在老年及身体状况不佳的慢性淋巴细胞白血病患者治疗中的治疗潜力。
J Hematol Oncol. 2015 Jul 14;8:85. doi: 10.1186/s13045-015-0165-x.
6
Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy.改进的疾病标志物表明，一名转移性去势抵抗性前列腺癌和慢性淋巴细胞白血病患者在接受活性细胞免疫治疗后出现双重反应。
J Hematol Oncol. 2015 May 14;8:51. doi: 10.1186/s13045-015-0149-x.
7
8
Ibrutinib, a novel agent in relapsed or refractory chronic lymphocytic leukemia.伊布替尼，一种用于复发或难治性慢性淋巴细胞白血病的新型药物。
Maedica (Bucur). 2014 Jun;9(2):217-8.
9
Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia.刺猬信号通路/GLI与PI3K信号通路在慢性淋巴细胞白血病起始和维持中的作用
Oncogene. 2015 Oct 16;34(42):5341-51. doi: 10.1038/onc.2014.450. Epub 2015 Feb 2.
10
Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.人类有机阳离子转运体1（hOCT1）作为苯达莫司汀摄取及慢性淋巴细胞白血病（CLL）细胞毒性的介质。
Pharmacogenomics J. 2015 Aug;15(4):363-71. doi: 10.1038/tpj.2014.77. Epub 2015 Jan 13.
本文引用的文献
1
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.硼替佐米与罗米地辛用于慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、惰性B细胞淋巴瘤、外周T细胞淋巴瘤或皮肤T细胞淋巴瘤患者的1期研究。
Leuk Lymphoma. 2017 Jun;58(6):1349-1357. doi: 10.1080/10428194.2016.1276287. Epub 2017 Jan 19.
2
Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.序贯使用奥法妥木单抗和来那度胺治疗复发难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤。
Leuk Lymphoma. 2015 Mar;56(3):645-9. doi: 10.3109/10428194.2014.935369.
3
Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.达沙替尼联合氟达拉滨治疗难治性慢性淋巴细胞白血病患者：一项多中心 2 期研究。
Leuk Res. 2014 Jan;38(1):34-41. doi: 10.1016/j.leukres.2013.10.004. Epub 2013 Oct 28.
4
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.苯达莫司汀治疗慢性淋巴细胞白血病：日常临床实践中不同临床和生物学预后因素的结果。
Am J Hematol. 2013 Nov;88(11):955-60. doi: 10.1002/ajh.23546. Epub 2013 Sep 9.
5
Cancer statistics, 2013.癌症统计数据，2013 年。
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
6
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.来那度胺和利妥昔单抗作为挽救疗法治疗复发或难治性慢性淋巴细胞白血病患者的 II 期研究。
J Clin Oncol. 2013 Feb 10;31(5):584-91. doi: 10.1200/JCO.2012.42.8623. Epub 2012 Dec 26.
7
Polo-like kinase 1 as target for cancer therapy.Polo-like kinase 1 作为癌症治疗的靶点。
Exp Hematol Oncol. 2012 Dec 10;1(1):38. doi: 10.1186/2162-3619-1-38.
8
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.CD19：B 细胞发育、淋巴瘤诊断和治疗的生物标志物。
Exp Hematol Oncol. 2012 Nov 29;1(1):36. doi: 10.1186/2162-3619-1-36.
9
Novel CD20 monoclonal antibodies for lymphoma therapy.新型 CD20 单克隆抗体在淋巴瘤治疗中的应用。
J Hematol Oncol. 2012 Oct 11;5:64. doi: 10.1186/1756-8722-5-64.
10
Therapeutic advancement of chronic lymphocytic leukemia.慢性淋巴细胞白血病的治疗进展。
J Hematol Oncol. 2012 Sep 16;5:55. doi: 10.1186/1756-8722-5-55.
Zotero 插件